Progression of liver fibrosis in blood donors infected with hepatitis C virus

Romanian Journal of Gastroenterology

Volumn 13, Issue 4, 2004, Pages 291-297

  Silva, Giovanni Faria ^a   Coelho, Kunie Iabuki Rabello ^a   Nishimura, Nancy F ^b   Soares, Elza Cotrim ^b  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Chronic hepatitis C; Fibrosis progression; Risk factors

Indexed keywords

ALANINE AMINOTRANSFERASE; ALCOHOL; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; VIRUS RNA;

ADULT; AGE; ALCOHOL CONSUMPTION; ARTICLE; BLOOD DONOR; BLOOD TRANSFUSION; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; ETHNIC GROUP; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; INTRAVENOUS DRUG ABUSE; LIVER BIOPSY; LIVER FIBROSIS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NONPARAMETRIC TEST; RISK FACTOR; VIRAL CONTAMINATION;

ADULT; BLOOD DONORS; DISEASE PROGRESSION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTORS; STATISTICS, NONPARAMETRIC;

EID: 11844289557     PISSN: 12214167     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Seeff LB. Natural history of hepatitis C. Hepatology 1997; 26 (Suppl 1): S21-S28.
2. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000; 20: 17-35.
3. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology 1997; 26 (Suppl 1): S34-S38.
4. EASL: International consensus conference on hepatitis C. Consensus Statement. J Hepatol 1999; 30: 956-961.
5. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-472.
6. Serfaty L, Aumaitre H, Chazouilleres O, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998; 27: 1435-1440.
7. Hu K-Q, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus related cirrhosis and history of parenteral exposure in the United States. Hepatology 1999; 29: 1311-1316.
8. Poynard T, Bedossa P, Opolon P for The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825-832.
9. Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34: 809-816.
10. Poynard T, Ratziu V, Benmanov Y, DiMartino V, Bedossa P, Opolon P. Fibrosis in the patients with chronic hepatitis C, detection and significance. Semin Liver Dis. 2000; 20: 47-55.
11. Shivakumar C, Jacob G. Predictors of liver-related complications in patients with chronic hepatitis C. Ann Med. 2000; 32: 588-591.
12. Stuyver L, Wyseur A, van Arnhem W, Hernandez F, Maertens G. Second generation line probe assay for hepatitis C virus genotyping. J Clin Microbiol 1996; 34: 2259-2266.
13. Silva GF, Nishimura NF, Caramori C, Soares EC. Influence of a regional habit on the hepatitis C virus infection: the role of Gluconergan®. Hepatology 2001; 34: 574A.
14. Seeff LB, Hollinger FB, Alter HJ, et al. Long-term mortality and morbidity of transfusion-associated Non-A, Non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute Collaborative study. Hepatology 2001; 33: 455-463.
15. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36: S35-S46.
16. Sobesky R, Mathurin P, Charlotte F, et al. Modeling the impact of interferon alpha treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. Gastroenterology 1999; 116: 378-386.
17. Berenguer M, Ferrel L, Watson J, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32: 673-684.
18. Tanaka E, Kiyosawa K. Natural history of acute hepatitis C. J Gastroenterol Hepatol 2000; 15 (Suppl): E97-E104.
19. Poynard T, McHutchison J, Manns M, et al, for the Peg-Fibrosis Project Group. Impact of pegylated interferon alpha-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303-1313.
20. Kim W, Gross JBJr, Poterucha JJ, Locke GR3rd, Dickson R. Outcome of hospital care of liver disease associated with hepatitis C in the United States. Hepatology 2001; 33: 201-206.
21. Ostapowicz G, Watson KJ, Locarnini SA, Desmond PV. Role of alcohol in the progression of liver disease caused by hepatitis C virus infection. Hepatology 1998; 27: 1730-1735.
22. Bonacini M, Groshen S, Yu MC, Govindarajan S, Lindsay KL. Chronic hepatitis C in ethnic minority patients evaluated in Los Angeles County. Am J Gastroenterol 2001; 96: 2438-2441.
23. Khan MH, Farrell GC, Byth K, et al. Which patients with hepatitis C develop liver complications? Hepatology 2000; 31: 513-520.
24. Kage M, Shimamatu K, Nakashima E, Kojiro M, Inoue O, Yano M. Long-term evolution of fibrosis from chronic hepatitis to cirrhosis in patients with hepatitis C: Morphometric analysis of repeated biopsies. Hepatology 1997; 25: 1028-1031.
25. Matsumura H, Moriyama M, Goto I, Tanaka NOkubo H, Arakawa Y. Natural course of progression of liver fibrosis in Japanese patients with chronic liver disease type C: a study of 527 patients at one stablishment. J Viral Hepat. 2000; 7: 268-275.
26. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-1364.
27. Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 2002; 36: 729-736.
28. Mathurin P, Moussalli J, Cadranel JF, et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998; 27: 868-872.
29. Jamal MM, Soni A, Quinn PG, Wheeler DE, Arora S, Johnston DE. Clinical features of hepatitis C infected patients with persistently normal alanine transaminase levels in the southwestern United States. Hepatology 1999; 30: 1307-1311.
30. Hervé S, Savoye G, Riachi G, et al. Chronic hepatitis C with normal or abnormal aminotransferase levels: is it the same entity? Eur J Gastroenterol Hepatol 2001; 13: 495-500.
31. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients, with chronic hepatitis C. J Hepatol 2001; 34: